https://www.selleckchem.com/pr....oducts/Telaprevir(VX
Regardless of LVSF, the primary endpoint incidence was significantly lower in patients treated with SCR [RLVSF 29.7% vs. 49.7%, hazard ratio (HR) = 0.46, 95% confidence interval (CI) 0.36-0.62, p 0.0001; PLVSF 7.3% vs. 16.9%, HR = 0.68, 95% CI 0.54-0.93, p = 0.0019], which was mainly driven by a reduction in cardiac death. The difference in survival probability was greater and became more pronounced over time in patients with RLVSF than with PLVSF (1-year, p = 0.197; 3-years, p = 0.048; 5-years, p = 0.036). SCR was assoc
Like
Comment
Share
